NBP insider trading
NasdaqGM HealthcareNOVABRIDGE BIOSCIENCES: insider trade history from SEC Form 4 filings.
About NOVABRIDGE BIOSCIENCES
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Company website: www.novabridge.com
NBP insider activity at a glance
FilingIQ tracks 16 insider transactions for NBP in filings since Apr 28, 2026. The most recent transaction is dated Sep 18, 2026.
Across the full history, 1 open-market purchases
and 7 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest NBP Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Most active insiders at NBP
By number of Form 4 lines in the last 180 days.
Frequently asked
- How many insider trades does FilingIQ track for NBP?
- FilingIQ tracks 16 Form 4 insider transactions for NBP (NOVABRIDGE BIOSCIENCES), covering filings from Apr 28, 2026 onwards. 8 of those are dated within the last 90 days.
- Are NBP insiders net buyers or net sellers?
- Across the full Form 4 history for NBP, 1 transactions (6%) were open-market purchases and 7 (44%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does NBP insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is NBP in?
- NOVABRIDGE BIOSCIENCES (NBP) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $276.40M.
Methodology & sources
Every NBP insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.